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The  occurrence  of  'biophenotypic  leukemias'  with  lymphoid  and  myeloid 
characteristics (1-5), together with cytogenetic or isozymic evidence of the clonal 
origin  of myeloid,  erythroid,  megakaryocytic,  and  lymphoid  cells  in  chronic 
myelogenous leukemia (6-9) suggest that leukemias may arise from pluripotent 
hematopoietic  stem  cells.  However, leukemia-derived  cell  lines  have not been 
established that  are capable of producing  mature  cells of several lineages,  i.e., 
that behave as functional mu[tipotentiai stem cells. In general, leukemic cell lines 
show restricted patterns of differentiation, behaving like committed progenitors 
adhering  imperfectly to early stages of a  dominant  program  of differentiation, 
but with a defect that blocks maturation. 
Two instances have recently been described in which an abrupt change in the 
lineage of origin of an acute leukemia suggested the involvement of a  multipo- 
tential  hematopoietic  stem cell.  In  each patient,  treatment  with the adenosine 
deaminase  (ADA) 1 inhibitor  deoxycoformycin was  associated with  conversion 
from a  T  lymphoblastic  to a  promyelocytic phenotype (i0,  1 i).  One  of these 
patients, a  16-yr-old boy with acute T  lymphoblastic leukemia of 2 mo duration, 
was studied extensively in our laboratory (11). After a 4 d course of deoxycofor- 
mycin the phenotype of his leukemia cells changed over a  3  d  period from T 
lymphoblastoid  to  promyelocytic,  resulting  in  death  from  leukostasis.  The  T 
lymphoid-to-myeloid conversion was confirmed by histochemical, immunologic, 
and biochemical criteria,  and  was found to be complete in all involved tissues, 
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including thymus, at autopsy.  The same abnormal  karyotype was found in pre- 
and  postconversion  leukemic  cells.  These  observations  led  us  to  suggest  that 
ADA inhibition had directly induced the T  lymphoid-to-myeloid transformation 
by altering  the  program  of differentiation of a  malignantly  transformed  stem 
cell  (11).  This  possibility  was  of particular  interest  in  view  of the  fact  that  a 
genetic deficiency of ADA  results  in  selective absence of lymphoid  lineages,  a 
defect that  could  theoretically result  from an  effect of purine  nucleosides  on 
lymphohematopoietic stein  cell differentiation.  To pursue the questions  raised 
by this  remarkable  response  to treatment  we  have established  a  cell line from 
this patient's leukemia cells. In this report we describe properties of this cell line, 
which we have named DU.528. 
Materials and Methods 
Materials.  Deoxyribonuclease I,  N-bydroxysuccinimidobiotin, nitroblue  tetrazolium 
(NBT), N~,O2'-dibutyryl  adenosine 3':5'-cyclic monophosphoric acid (dbcAMP), phorbol- 
12-myristate-13-acetate (PMA),  5-azacytidine,  5-aza-2'-deoxycytidine, 2-aminoethyliso- 
thiouronium bromide hydrobromide, ethidium bromide, heparin, and 3'3'-diaminoben- 
zidine were obtained from Sigma Chemical Co. (St. Louis, MO), as were staining kits for 
c~-naphthyl butyrate esterase, naphthol AS-D chloroacetate esterase, periodic acid-Schiff, 
and myeloperoxidase. Alsever's solution and giant cell tumor (GCT)-conditioned medium 
were purchased from Gibco Laboratories (Grand Island, NY); purified phytohemaggluti- 
nin from Burroughs Wellcome Co. (Research Triangle Park, NC);  HSI-LoSM medium 
from Hybridoma Sciences (Atlanta,  GA);  and Diff-Quik stain from Scientific Products, 
Inc. (Detroit, MI). TP-5, an analog of thymopentin, was provided by Dr. Gideon Goldstein, 
Ortho  Pharmaceutical  Corp.  (Raritan,  NJ),  and  2'-deoxycoformycin (Pentostatin)  by 
Warner Lambert-Parke Davis (Ann Arbor, MI). 
Cell Growth and Culture Methods.  Ceils were routinely cultured in standard medium 
consisting of RPM1  1640 (Gibco Laboratories) supplemented with 10% horse serum and 
10%  heat-inactivated fetal calf serum  309 both from Gibco Laboratories, nonessential 
amino acids,  1 mM pyruvate, and 2 mM glutamine, under an atmosphere of 5% CO2 in 
air at 37°C. Thawing medium consisted of RPMI  1640 containing 25% heat-inactivated 
fetal calf serum  309,  penicillin/streptomycin, 20  U  heparin/ml,  and  1 rag/100  ml  of 
deoxyribonuclease I.  Cloning  was  performed by limiting dilution  in  standard  growth 
medium (see Results).  All experiments were performed with cultures in the logarithmic 
phase of growth. Cultures were deemed free of mycoplasma contamination by the inability 
of conditioned medium in  which the cells  had been grown to cause the conversion of 
deoxyadenosine to adenine (plus 5 uM deoxycoformycin to inhibit ADA). 
Morphological, Cytochemical, Functional, and Cytogenetic Characterization.  Standard dif- 
ferential  counts  were  performed  on  cytocentrifuge (Shandon  II;  Shandon  Southern 
Instruments Inc., Sewickley, PA) preparations of cells stained with the Diff-Quick modi- 
fication of the Wright's-Giemsa technique (12).  Cytochemical tests included staining for 
myeloperoxidase (MPO) (13), periodic acid-Schiff (PAS) (14), c~-naphthyl acetate esterase 
(nonspecific esterase [NSE])  (14),  and a-napthyl-butyrate esterase (14).  NBT reduction 
was assessed as previously described (15). The percentage of cells synthesizing hemoglobin 
was  determined  by  hemocytometer count after staining  with  benzidine  (16).  Rosette 
formation with sheep erythrocytes (E rosettes) was evaluated as described (17). Karyotyp- 
ing was performed by standard methodology. Briefly, cultured cells were arrested with 
colchicine, treated with hypotonic KCI, and fixed with methanol/acetic acid (3:1). Giemsa- 
trypsin banding was performed as described (18).  For each culture at  least 50 spreads 
were  examined to  determine chromosome number.  Complete  karyotype analysis  was 
performed on 10 spreads for the parent cell line and on 7-10 spreads for clones. 
Analysis of Cell Surface Markers.  Anti-human Leu-2b, anti-human Leu-3a +  3b, anti- 
human  Leu-5, anti-human  Leu-6, anti-human  HLA-DR,  anti-human  Leu°M2,  anti- 
human  Leu-M3, anti-human  transferrin  receptor, and avidin-phycoerythrin conjugate KURTZBERG,  BIGNER,  AND  HERSHFIELD  1563 
were obtained from Becton, Dickinson & Co. (Mountain  View, CA); anti-B1 and anti-B2 
from Coulter Electronics, Inc. (Hialeah, FL); anti-BA1  from Hybritech, Inc. (San Diego, 
CA); and affinity-purified, fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse 
IgG from  Tago  Inc.  (Burlingame,  CA).  MY-10  monoclonal  antibody (19)  was  kindly 
provided by Dr. Curt Civin, Johns Hopkins Oncology Center (Baltimore, MD).  P3x63/ 
Ag/8 mouse myeloma cell-induced mouse ascitic fluid, anti-TAC (anti-interleukin 2 [IL- 
2]  receptor  [20]),  and  3A1  (21)  monoclonal  antibodies  were provided  by Dr.  Barton 
Haynes, and the DU-HL60-3 (22) monoclonal antibody by Dr. Richard Metzgar, both of 
Duke University Medical Center. Terminal deoxynucleotidyl transferase immunoperoxi- 
dase kit (Supertechs, Inc., Bethesda, MD) was provided by Dr. Fred Bollum, Uniformed 
Services University of the Health Sciences. 
10  6  Cells  in  standard  medium  were  washed  twice  with  phosphate-buffered  saline 
containing  1%  bovine  serum  albumin  and  0.1%  sodium  azide  (PBS/BSA),  and  then 
incubated with  1:50 to  1:200 dilutions of monoclonal antibody for 30 min at 4°C  in a 
microtiter (96 well,  round bottomed) plate. After two washes with PBS/BSA, cells were 
incubated with affinity-purified, FITC-labeled goat anti-mouse IgG (1:100) for 30 min at 
4 ° C. After two additional washes, cells were resuspended in PBS/BSA. Membrane staining 
was assessed immediately by either fluorescence microscopy or fluorescence-activated cell 
sorter (FACS) analysis of 10,000  cells per sample, performed on an Ortho 50 cytofluo- 
rograph (Ortho Pharmaceutical Corp.). Alternatively, the cells were fixed by the addition 
of 37% formaldehyde (10 #l/ml of cell suspension) and stored at 4 °C in the dark for later 
FACS  analysis.  In each  assay, background  fluorescence was determined  by incubating 
cells with P3x63/Ag/8 ascitic fluid (control murine myeloma protein), instead of specific 
primary antibody, and by incubation  with  FITC goat anti-mouse IgG alone.  The per- 
centage of nonviable cells in unfixed preparations was determined by a hemocytometer 
count of cells that stained with trypan blue or by FACS analysis of cells that stained with 
ethidium bromide (0.1  mg/ml, 5 min exposure). 
Double parameter fluorescence analysis was used to determine whether two different 
membrane antigens,  3A1,  a  T  cell  marker, and  DU-HL60-3, a  myeloid marker,  were 
both present on individual cells.  All incubations were for 30 min at 4°C in the dark and 
cells were washed with PBS/BSA without azide. 106 Cells were washed twice and incubated 
with  biotinylated  DU-HL60-3  (DU-HL60-3  B,  prepared  as  described  [23]).  After  two 
washes the cells were counterstained with 100 #1 of phycoerythrin-avidin (PE-AV) (1:100; 
Becton,  Dickinson  &  Co.)  Cells  were  again  washed  twice  and  then  incubated  with 
fluoresceinated 3A1  (3Al*) prepared by Dr. Barton Haynes. After two more washes the 
cells were resuspended and fixed with formaldehyde as described above. 10,000 cells per 
sample were analyzed for red (DU-HL60-3  B) and green (3Al*) fluorescence on an Epics 
5  FACS  (Coulter Electronics,  Inc.).  In each experiment, appropriate negative controls 
were used to establish gates for quantitating specific fluorescence in the red and green 
channels  and  for simultaneous  expression  of both  red  and  green  fluorescence.  These 
controls  included  similarly processed cells  sequentially  incubated  with  (a)  biotinylated 
goat anti-mouse IgG, PE-AV, and directly fluoresceinated P3x63/Ag/8 (double negative 
control); (b) 3A 1" alone (green positive, red negative control); and (c) DU-HL60-3" and 
PE-AV (red positive, green negative control). 
Crude Growth Supplements.  Media conditioned by human peripheral blood leukocytes 
(LCM)  for  7  d  in  the  presence  of  1%  (vol/vol)  phytohemagglutinin  and  10%  heat- 
inactivated  fetal  calf serum  309  (PHA-LCM)  (24),  and  media  conditioned  by human 
peripheral blood T cells (TCM) (obtained by E rosette separation) for 72 h in the presence 
of 1% PHA (PHA-TCM) (25), were prepared as described. 
Results 
Establishment  and  Cloning  of the  DU.528  Cell  Line.  Details  of the  patient's 
clinical course and phenotypic conversion have been described (11).  Leukapher- 
esis  was performed at  diagnosis,  before  treatment,  when  the  total  white  count 
was  >100,000/#1  (>90%  T  lymphoblasts).  After  density  gradient  purification 1564  A  HUMAN  LYMPHOHEMOPOIETIC STEM CELL  LINE 
cells were stored in the presence of 12% dimethylsulfoxide in liquid nitrogen.  A 
vial  (109  cells)  was  thawed  by swirling  for  2  min  in  a  37°C  water  bath,  then 
diluted  fourfold  with  thawing medium over  10-15  rain.  The culture  was then 
further diluted in standard  medium to 5  ×  106  cells/ml.  After 2  wk the culture 
was maintained at 0.8-2  x  106 cells/ml, and, after 10-12 mo, at densities as low 
as 2  ×  10 ~ celis/ml. After  18 mo in continuous culture, the cells were cloned by 
limiting dilution in standard medium.  190-200  wells of 96-well microtiter plates 
were set up at each of several cell densities (1,000  to  10 cells per well). Growth 
occurred in all wells at  1,000  and  500 cells per well;  in 48 of 192  wells at  100 
cells per well; in  5  of 191  wells at 50 cells per well; and in no wells at either 25 
or  10 cells per well. Each of the five wells that yielded growth at the 50 cells per 
well density was expanded for further characterization. 
Over the  first  10  mo of culture  in  standard  medium  containing  10%  horse 
serum and  10% heated fetal calf serum, the population doubling time of DU.528 
cells gradually diminished from 7-10 d  to 48-96 h  (Fig.  1). On several occasions 
over a  2  yr period we have reevaluated the serum requirements of the cell line. 
GrOwth was not supported by medium containing 20% fetal calf serum alone; in 
20% horse serum the cells grew at 70-80%  of the rate in standard medium, for 
-3  wk, but then gradually lost viability. Growth was not influenced by either of 
two  commercial  medium  supplements  (GCT,  a  source  of  colony-stimulating 
activity  [26],  and  HSI-LoSM,  a  supplement  designed  to  support  growth  of 
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FXGURE  1.  Growth curves for DU.528 during initial period in culture (A) and after 2 yr in 
continuous  culture  (B). (A) Growth  characteristics during the initial period  in culture.  No 
increase in  cell number was observed during the first month after thawing, after which a 
population  doubling time of 10-14 d was observed. (B) Growth of the established cell line 
after 2 yr in culture, demonstrating  a population doubling time of 48-72 h. KURTZBERG,  B1GNER,  AND  HERSHFIELD  1565 
source of burst-promoting activity (24),  increased the growth rate  by  -30%. 
PHA-TCM,  a  crude  preparation  of T  cell  growth  factor  (25),  was  strongly 
growth inhibitory (>50% inhibition when present as a  5% addition to standard 
medium) (Fig. 2). The growth characteristics of DU.528 clones are similar to the 
parent line. 
All cells examined from the DU.528 cell line and its clones showed the stemline 
karyotype: 46, XY,- 14, +( 1; 14)(p33;q 11 ),del( 1  )(p33),+del(1 )(q 11),dei( 13)(q 14) 
(Fig. 3). This is the same karyotype found in the patient's leukemia cells, both at 
diagnosis and after phenotypic conversion (11) (the  13q- marker was present in 
freshly obtained leukemia cells from the patient although it was not shown in 
the original publication). No cells showed a normal karyotype, which was present 
in the patient's mitogen-stimulated (nonmalignant) peripheral blood lymphocytes 
(11). In addition to the DU.528 cell line, derived from the patient's pretreatment 
leukemia cells, we have also established a long-term line from circulating leukemia 
cells obtained from the patient after phenotypic conversion. The karyotype of 
this latter cell line is identical to that shown in Fig. 3, and its characteristics are 
the same as those described below for DU.528. 
Spontaneous, Multilineage Differentiation.  When first placed in culture DU.528 
cells  had  uniform  T  lymphoblastoid  morphology  (large,  often  cleft,  nuclei; 
prominent nucleoli; scant, basophilic cytoplasm) (Fig. 4A). Consistent with this 
morphology, these cells did not stain for myeloperoxidase or nonspecific esterase 
(myeloid and  monocytoid properties,  respectively), but  >90%  of cells stained 
weakly for butyryl esterase in a  cytoplasmic distribution with a  fine, granular 
pattern  characteristic of lymphoid cells.  An  occasional cell  was  PAS positive. 
This initial cell population reacted with the 3A 1 monoclonal antibody, a pan T 
cell marker of undifferentiated T  cell precursors in the embryonic thymus (21, 
27,  28),  but not with a  monoclonal antibody (DU-HL60-3)  raised against the 
HL60 promyelocytic cell line, which detects cells of the granulocyte/monocyte 
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FIOURE  2.  Effect of PHA-TCM on the growth of DU.528 ceils. DU.528 cells were cultured 
in standard medium containing the indicated concentrations of PHA-TCM. The results are 
from one of four identical experiments conducted over 30 mo. A growth-inhibiting effect was 
observed on all occasions. 1566  A  HUMAN  LYMPHOHEMOPOIETIC  STEM  CELL  LINE 
FIGURE 3.  Karyotype of DU.528  cell line.  The  No.  1 chromosomes are replaced by two 
deleted No,  !  chromosomes and one product of a translocation between No.  1 and No.  14. 
One No.  13 is replaced by a deleted No.  13 chromosome. There are no other numerical or 
structural abnormalities. The arrangement shown  is from an analysis performed on DU.528 
cells that bad been in culture continuously for >2 yr. Karyotypes were analyzed for four of 
the five clones of DU.528. Two clones (2 and 5) showed only the stemline karyotype; 50% of 
spreads from clone 3 had the stemline karyotype and 50% had the same karyotype with a new 
i(9q) replacing one copy of chromosome 9.  A single spread from clone 4  had the stemline 
karyotype; all others contained an extra copy of chromosome 17 in addition to all the changes 
seen in the parent cell line. 
During  the  3rd  wk  in  culture we  noted  the presence of many  immature  cells 
of indeterminate  lineage and  some cells with distinct myeloid morphology  (Fig. 
4B).  By  2  mo  the  culture  was  composed  primarily of myeloid cells,  including 
mature  segmented  neutrophils  and  large  mononuclear  cells  (Fig.  4C).  The 
change  in  morphology  was  accompanied  by  acquisition  of  the  DU-HL60-3 
antigen,  although  most  cells continued  to  express  the  3A1  antigen  (Fig.  5A). 
Over the next 2  wk terminally differentiated myeloid cells disappeared and were 
replaced by immature  cells with blast morphology,  which expressed 3A 1 but not 
DU-HL60-3  (Figs.  4D  and  5A).  A  second  vial  of  cryopreserved  cells  from 
FIGURE 4.  Change  in  morphology of DU.528  cells  during  the  first  10  wk  in  culture. 
Photomicrographs (x470)  of Wright's-Giemsa-stained cytospin preparations made  on  the 
following days after thawing: day 1, upper  left; day 30, upper  right; day 55, lower left; day 64, 
lower right. KURTZBERG,  B1GNER,  AND  HERSHFIELD  1567 1568  A  HUMAN LYMPHOHEMOPOIETIC STEM CELL LINE 
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FIGURE 5.  Spontaneous change in surface antigen expression on DU.528 cells during initial 
10 wk in culture. (A) Results from analysis  of the culture described in Fig. 4; (B) Results from 
similar analyses of a  second culture  established independently from  cryopreserved cells 
obtained from the patient at time of diagnosis. On the indicated days after thawing, samples 
of the cultures were removed for FACS analysis to determine the percentages of cells that 
expressed the 3A1 (solid lines) and DU-HL60-3 (dashed lines) antigens. 
diagnosis was thawed and studied more closely. A  similar fluctuation in surface 
antigenic phenotype (Fig. 5B) and morphology (not shown) was observed. 
The observed fluctuation in phenotype could have resulted from the presence 
of two  distinct  populations  of cells,  one  lymphoid  and  the  other  a  myeloid 
progenitor, or it could have resulted from differentiation of cells with an initially 
T  lymphoblastoid phenotype along a myeloid pathway. The latter possibility was 
suggested by the finding on some occasions that both the 3A1  and DU-HL60-3 
antigens were present on >50% of cells (e.g., days 40-50, Fig. 5B). Simultaneous 
expression of the T  cell and myeloid markers on individual cells was confirmed 
by dual parameter  immunofluorescence cytofluorographic analysis.  In  the ex- 
periment  shown  in  Fig.  6,  performed  after  12  wk  of culture,  17%  of cells 
expressed both markers. At the time of thawing, <2% of these cells were found 
to simultaneously express both markers. 
We  have  monitored  the  morphologic,  histochemical,  and  surface  antigenic 
characteristics of DU.528  cells at weekly or biweekly intervals during the first 
year in culture and at frequent intervals during the second year (Tables I  and 
II,  Fig.  7).  The most striking property of the cell line is its heterogeneity. At 
most times cultures of DU.528  and each of its clones were composed predomi- 
nantly of undifferentiated,  lymphoblastoid cells.  However,  there  were  almost 
always some cells representing both lymphoid and nonlymphoid lineages at many 
stages of differentiation. At unpredictable intervals the parental DU.528 cell line 
and  its  clones  underwent  waves of spontaneous  differentiation similar  to  the 
behavior  observed  during  the  first  2  mo  in  culture,  although  tbe  intervals 
between  these  events became  longer and  the  percentages  of mature  cells  de- 
creased.  The  percentage  of cells simultaneously expressing  the  3A1  and  DU- 
HL60-3  surface antigens, determined by dual-label  immunofluorescence cyto- 
fluorographic analysis, fluctuated from < 1 to 84% in cultures of DU.528 sampled 
randomly over the first 2 yr in continuous culture, and has remained <5% during KURTZBERG,  BIGNER,  AND  HERSHF1ELD 
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FIGURE 6.  Simultaneous expression of T  cell and myeloid surface antigens by DU.528 cells. 
Dual parameter analysis for expression of the 3A 1 pan T  cell antigen and DU-HL60-3 myeloid 
antigen  was  performed  as  described  in  Materials  and  Methods.  The  analyses  shown  were 
performed after  12 wk in culture. 64% of the cells expressed the 3AI antigen,  23% the DU- 
HL60-3  antigen,  and  17%  expressed  both  markers.  Similar analyses  performed  at  various 
times during 2 yr of continuous culture revealed coexpression of these antigens by from <1 
to 84% of cells. 
TABLE  I 
Morphologic Class~cation of DU. 528 Cell Line During Continuous Culture 
Myelocyte  Band and  Monocyte  Megakaryo-  Nucleated 
Days in  Blast  Mature  Promyelo-  and mere-  segmented  Eosinophil  and histio- 
culture  lymphocyte  cyte  myelocyte  neutrophil  cyte  cyte  erythrocyte 
%  %  %  %  %  %  %  %  % 
2  95  5 
18  16  16  7  8  26  16  3  9 
23  3  6  2  7  8  30  9  18  7 
60  25  8  9  31  3  15  2  7 
94  44  5  7  20  17  2  5 
122  78  2  5  13  5 
764  64  1  5  3  1  21  5 
785  23  5  1  15  17  1  26  11 
843  90  2  1  1  2  4 
Cell classification was determined by differential count of at least 200 Wright's-stained  cells, which were prepared from logarithmically 
gr~wlng cultures by cytocentrifugation. The data were chosen  to illustrate the diversity present during the initial 3 mo and after >2 
yr in continuous culture. Except  for cells with a megakaryocytic  morphology, which are no longer seen, all other cell types listed in 
the table continue to be found on some days. 
the last half of the 3rd yr. DU.528  cells maintained continuously in culture for 
>2.5 yr show little evidence of spontaneous nonlymphoid differentiation. 
The  photomicrographs  in  Fig.  7,  A-C  were made  from a  single  culture  of 
DU.528  cells that had been in culture continuously for >2 yr. Fig.  7A  shows a 1570  A  HUMAN  LYMPHOHEMOPOIETIC  STEM  CELL  LINE 
TABLE  II 
Surface Antigens Expressed by DU.528 
Percent positive (range) 
Monoclonal antibody  Specificity  Undifferen-  Differen- 
tiated  tiated 
culture  culture 
3A l  Pan T  cell  39-99  48-98 
Leu-2b, OKT8  Cytotoxic T  cells  <1-6  8-23 
Leu-3a, OKT4  Helper T  cells  <1-7  8-63 
Leu-4  Pan T  cell  2-5  NT 
Leu-5, OKTI 1  E rosette receptor  <1-8  10-82 
Leu-6, OKT6  Thymocytes  <1-7  1-46 
TR, 5E9  Transferrin receptor  26-84  69-84 
HLA-DR,  IA  B cells, monocytes  <1-6  2-84 
MY-10  Hematopoietic progenitors  <1-39  NT 
DU-H L60-3  Granulocytes  3-13  5-87 
Leu-M2  Monocytes  3- l 0  3-24 
Leu-M3  Monocytes, macrophages  <1-6  2-6 
TAC  IL-2 receptor  2-38  43-90 
TDT  T  celI subset  <I-10  <1-10 
Undifferentiated cultures contained a homogeneous population of undifferentiated blasts. Differen- 
tiated  cultures  are  those  in  which  >10%  of cells  had  morphologic  characteristics of erythroid, 
myeloid, or monocytoid lineages at various stages of maturity.  NT,  not tested.  Each antibody was 
tested by FACS analysis on at least four occasions and analyses were performed on >60 occasions 
over 2 yr. 
cluster containing a blast, a dyserythropoietic erythroid precursor, a segmented 
neutrophil, a lymphocyte, and a monocyte; Fig. 7B, several erythroid cells among 
numerous immature  cells of indeterminate  lineage;  Fig.  7 C, two neutrophils,  a 
monocyte, and two undifferentiated blasts. Histochemical studies and functional 
characteristics were consistent with cell morphology. Thus, staining with benzi- 
dine demonstrated  hemoglobin  synthesis by erythroid  cells (Fig.  7D);  promye- 
locytic cells contained characteristic myeloperoxidase-positive granules (Fig. 7E) 
and monocytic cells stained with nonspecific esterase, which was not inhibited b); 
fluoride (Fig. 7 F). Typical E rosetting of T  lymphocytes was observed (Fig. 7 G). 
Spontaneous  function  of macrophages  was strikingly  demonstrated  in  DU.528 
cultures by the finding of engulfed erythroid nuclei in histiocytic cells (erythro- 
phagocytosis,  a  function  of  bone  marrow  macrophages  in  some  pathologic 
conditions) (Fig.  7H). 
At times when  cultures  of DU.528 appeared  uniformly undifferentiated  the 
predominant  marker expressed was 3A1  (Table II,  'Undifferentiated'  column). 
These cells also expressed the transferrin  receptor, a lineage-nonspecific marker 
present on actively replicating cells (27, 29). Up to 40% of undifferentiated cells 
expressed  the  MY-10  antigen,  which  has  been  reported  to  occur  on  a  small 
fraction  of bone marrow  cells enriched  for myeloid-erythroid progenitor  cells 
(19). Terminal deoxynucleotidyltransferase, a marker of T  cell precur:~ors in the 
thymic cortex as well as a  minor population of bone marrow lymphoid progeni- 
tors (30), was detectable on <10% of DU.528 cells. <8% of these undifferentiated 
cells expressed  the  E  rosette  receptor or the  T4  or T8  T  cell differentiation KURTZBERG,  BIGNER,  AND  HERSHFIELD  1571 
FIGURE 7.  Diversity of hematopoietic cell types present in cultures of the DU.528 cell line. 
(A-C) Wright's-Giemsa-stained  cytospin preparations (x 1,000) of DU.528 clone 1. (D) Benzi- 
dine-stained DU.528 cell. (E) Promyelocyte cells in DU.528 culture stained from myeloperox- 
idase (granules). (F) Sheep erythrocyte-rosetted  DU.528 cell. (G) Wright's-Giemsa-stained 
cytospin preparation of DU.528 culture (× 1,000) showing a large mononuclear histiocytic cell 
containing an engulfed erythroid nucleus (arrow, 'erythrophagocytosis'). bl, blast; l, lympho- 
cyte; n, neutrophil; m, monocyte; E, nucleated erythrocyte. 1572  A  HUMAN  LYMPHOHEMOPOIETIC STEM  CELL  LINE 
antigens,  but  up to  38%  expressed the  T  cell growth  factor (IL-2) receptor,  as 
indicated by reactivity with the anti-TAC monoclonal antibody (20). 
In  cultures  with  >10%  of cells  showing  myeloid  or  erythroid  morphology 
(Table II, 'Differentiated' column), we observed a wider range of surface antigen 
expression. Reactivity with the DU-HL60-3 and Leu-M3 monoclonal antibodies, 
and expression of HLA-DR antigens was consistent with the presence of mono- 
cytes and macrophages.  In addition,  on many occasions a  significant percentage 
of cells expressed  some T  cell differentiation  antigens,  including  T6,  T4,  and 
T8. Expression of the T3 antigen, which correlates with expression of the T  cell 
antigen receptor (31), was not seen. There was generally a  greater frequency of 
anti-TAC-positive  cells  in  these  more  differentiated  populations  than  in  uni- 
formly undifferentiated  cultures.  Markers of B  cells have not been  extensively 
studied.  The B  cell differentiation antigens B1,  B2, and BA1  (32) were present 
on  0-10%  of  DU.528  cells.  Further  assessment  of  the  possibility  of  B  cell 
differentiation and function is in progress. 
Response to Inducers of  Differentiation.  The data summarized in Table III show 
the  response  of clone  DU.528-3  to  agents  that  have  frequently  been  used  to 
induce maturation of myeioid and erythroid leukemia cells and cell lines (phor- 
bols, dibutryl  cyclic AMP,  5'-azacytidine, and azadeoxycytidine).  Each of these 
agents  had  a  clear-cut  effect,  resulting  in  increases  in  the  percentages  of cells 
that expressed myeioperoxidase and nonspecific esterase (histochemical markers 
for granulocytes and monocytes, respectively), and in the ability to reduce NBT, 
a  functional assay for mature granulocytes. 
In  several  experiments,  during  the  first  2~/2 yr  in  culture,  we  have  asked 
whether  the  ADA substrates,  adenosine  (Ado)  and  2'-deoxyadenosine (dAdo), 
in the presence of the ADA inhibitor deoxycoformycin, can induce  undifferen- 
tiated  DU.528  cells to  express markers of myeloid differentiation.  In a  repre- 
sentative  experiment,  we monitored  effects on  the  growth  of clone  DU.528-4 
and on its expression of the DU-HL60-3 antigen and a  DR class II histocompat- 
ibility antigen (Table IV, experiment A). As has been found in studies of a  large 
TABLE  III 
Induction of Myeloid Maturation in DU.528 
Additions  Range tested 
Maximum percent 
positive cells 
NBT  MPO  NSE 
M 
None (control)  --  12  1  12 
dbcAMP  10  -6 to 10  -4  68  59  58 
PMA  1.6 × l0 -9 to 1.6 x  10  -7  50  84  70 
5-Azadeoxycytidine  10  -9 to 10  -4  5  62  46 
5-Azacytidine  5 x  10  -s to 10  -5  43  23  49 
NBT, reduction  of nitroblue  tetrazolium;  MPO, myeloperoxidase; NSE, nonspecific 
esterase;  dbcAMP,  dibutyryl  cyclic AMP; PMA, phorbol  myristate  acetate.  Clone 
DU.528-3 cells, which were morphologically immature (60% 3Al-positive;  10% DU- 
HL60-3 positive), were incubated for 4 d in the presence of the compounds listed, over 
the concentration  range indicated, and then evaluated histochemically as described in 
Materials and Methods. KURTZBERG,  BIGNER,  AND  HERSHF1ELD 
TABLE  IV 
Effects of ADA Inhibition  and ADA Substrates on Differentiation  of DU.528 
1573 
DU-HL60-3  DR 
Day of  Total 
Additions*  treat-  cells*  Percent  Total  Percent  Total 
ment  positive  cells  0  positive  cells§ 
Exp. A. DU528 clone 4 
None  0  1.8  2  0.4  1  0.2 
None  6  18.7  8  14.6  3  5.0 
Uri20  6  18.4  8  14.0  5  8.6 
dCF~  6  17.1  13  21.9  5  8.9 
plus Ado5  6  15.8  10  15.6  6  10.1 
plus Ado20  6  3.5  60  21.3  49  17.4 
plus Ado~0Uri~o  6  16.8  9  14.3  6  10.7 
plus dAdos  6  11.5  18  21.1  8  8.8 
plus dAdo2o  6  2.3  75  17.1  79  17.9 
plus dAdo~0AdosUri20  6  5.3  62  32.9  84  44.5 
Exp. B. DU528, uncloned 
None  6  14.3  1  1.3  1  1.3 
dCFsdAdo20Ado~Uri20  6  4.2  48  20.2  60  25.0 
Undifferentiated  cultures  (>95%  blasts)  were  incubated  in  standard  medium  containing  the 
indicated compounds. On days 0 and 6 cells were counted and the expression of DU-HL60-3 and 
HLA-DR antigens analyzed by FACS. 
* Uri, uridine; dCF, deoxycoformycin; Ado, adenosine; dAdo, deoxyadenosine. Subscripts indicate 
concentration (ttM). 
* Cells/ml X 10  -~. 
§ Cells/ml x  10  -4. 
number of human and murine lymphoblastoid cell lines, deoxycoformycin alone 
is nontoxic in vitro, but it potentiates the toxicity of Ado and dAdo (33). In the 
absence of ADA substrates, deoxycoformycin had little effect on either growth 
or marker  expression.  In  the  presence  of deoxycoformycin, growth-inhibiting 
concentrations  (20  ttM) of both  Ado and  dAdo induced  60 and  75%  of cells, 
respectively, to express the DU-HL60-3 antigen  (vs. <10% in controls), and 49 
and 79% to express the DR antigen (vs. <5% in controls). Despite their inhibition 
of cell growth, Ado and dAdo treatment resulted in increases of 1.4- and 2-fold 
in the absolute number of cells expressing these markers. Uridine, which bypasses 
the block in de novo pyrimidine synthesis caused by low concentrations of Ado 
(33,  34),  prevented  the  effects of 20  ttM  Ado on  both  cell  growth  and  new 
marker  expression.  Of interest,  the  combination  of 5  #M  Ado  plus  uridine, 
which  had  no effect on  growth  or antigen  expression,  diminished  slightly  the 
growth-inhibiting  effect of 20  ttM  dAdo.  Under  these conditions  the  treated 
cultures contained twofold and fivefold more DU-HL60-3- and DR-positive cells 
than  controls.  Even more striking  effects were observed with parental  DU.528 
cells (Table IV, experiment  B), which were in a  more undifferentiated  state at 
the time of this experiment. 
The  induction  of expression  of myeloid  markers  by  Ado  and  dAdo  was 
observed in  15  separate experiments  conducted with  DU.528  cells during  the 
first 21/2 yr in culture.  However, with cells that have been maintained in contin- 
uous  culture  for  >2.5  yr,  we  have  not  observed  response  to  purines  or  to 1574  A  HUMAN  LYMPHOHEMOPOIETIC  STEM  CELL  LINE 
conventional differentiating  agents.  As noted above, these cells also show little 
evidence  of spontaneous  differentiation.  It  thus  appears  that  on  prolonged 
continuous culture the  line  has lost the capacity for differentiation,  or that  we 
have  selected for a  proliferating,  nondifferentiating  population.  Early  passage 
cells continue to display the capacity for differentiation. 
Discussion 
Treatment of leukemias with pharmacologic and physiologic agents that induce 
differentiation in vitro is currently being considered, with the aim of overcoming 
the block in terminal  maturation  (35, 36). In addition to a temporal association 
between drug  administration  and  change  in  phenotype,  proof of an  effect on 
differentiation,  rather  than  selective cytotoxicity,  requires  evidence  that  cells 
with a  new phenotype are derived from the leukemic clone.  Demonstration  of 
some  direct  action  of the  inducer  on  the  target  cell  in  vivo  would  also  be 
desirable, as would reproduction of the differentiative response in reconstruction 
experiments with the target cells in vitro. 
In the patient  from whom the DU.528 cell line was derived we documented 
complete T  lymphoid-to-myeloid transformation  during a  7 d period beginning 
with the start of deoxycoformycin infusion (11).  Over this period the leukemia 
cell count was stable, elevated in the 70,000-80,000 cells/#l range, kinetics that 
suggested  a  precursor-product  relationship.  We  have  demonstrated  effective 
ADA inhibition and consequent biochemical abnormalities (dATP and S-adeno- 
sylhomocysteine accumulation) in leukemia cells during the period of conversion, 
and we have shown that pretreatment T  lymphoblasts and post-deoxycoformycin 
treatment  promyelocytes had  the  same abnormal  karyotype.  The  presence  of 
this  karyotype in  the DU.528 cell  line and  its clones, as well as in  the cell  line 
established from cells obtained after phenotypic conversion, establishes that these 
cell lines are also derived from the same neoplastic clone. For >2 yr in continuous 
culture these cells retained  the capacity for proliferation  (self-renewal) and  for 
generation  of progeny  of (at  least)  three  lineages:  T  lymphoid,  granulocytic/ 
monocytic, and erytbroid. These characteristics provide strong support for our 
conclusion (11) that  leukemia in this patient arose from a pluripotent  stem cell 
capable of lymphoid and myeloid differentiation. 
Leukemia cells from patients  with acute myeloid leukemias have been found 
to  coexpress  various  markers  of myeloid,  erythroid,  and  lymphoid  lineages 
('lineage infidelity') (37-40).  Though  we have not systematically evaluated this 
phenomenon, some degree of lineage infidelity is suggested by the coexpression 
of the  3A1  T  cell and  DU-HL60-3 myeloid antigens  on  DU.528 cells at some 
stages  of differentiation.  It  is  unclear  whether  lineage  infidelity  represents  a 
pathologically disordered pattern of gene expression that results from malignant 
transformation,  or whether  transient  expression of markers  of all lineages is a 
normal  characteristic  of pluripotent  stem  cells.  The  mature  morphology and 
functional  characteristics  of differentiated  DU.528 cells suggests the operation 
of well-coordinated, lineage-specific programs of differentiation. 
Proliferation  and  differentiation  of DU.528  occur  without  the  addition  of 
factors other than  serum.  These processes may be truly autonomous or under 
some form of autocrine regulation. The latter term, in its usual context (41, 42), KURTZBERG,  BIGNER,  AND  HERSHFIELD  1575 
refers  to the control  of tumor cell growth  by factors produced by the  tumor 
itself. In the special case of DU.528, cultures of which vary from almost entirely 
undifferentiated  cells to mixed  populations  displaying a  wide range  of pheno- 
types, factors produced by a  subpopulation  of DU.528  cells of one lineage or 
stage of maturation  may influence the differentiation of another subpopulation 
of immature cells with differentiative potential.  On the other hand, differentia- 
tion of DU.528 cells may be a  stochastic process, as has been shown to be the 
case in studies of in vitro differentiation of mouse and human bone marrow (43, 
44). Efforts to examine these possibilities are in progress. 
The characteristics of multipotential  DU.528 cells are unclear,  but they pre- 
sumably have an  undifferentiated  morphology and express few lineage-specific 
markers.  Recent reports (45, 46) have suggested that the first cells to appear in 
the embryonic mouse thymus, thought to be stem cells, express the receptor for 
T  cell growth factor (IL-2) but neither the Lyt-2 (cytotoxic phenotype) or L3T4 
(helper phenotype) antigens. Proliferation of these cells is I L-2 independent. The 
antigen  expressed  most consistently  by undifferentiated  DU.528  cells is  3A1, 
which is thought to be the first T  cell marker expressed on prothymocytes in the 
embryonic human thymus (28). In some populations of undifferentiated DU.528 
cells we observed cells with the phenotype 3A 1  +, anti-TAC + (IL-2 receptor), T8- 
(cytotoxic), T4-  (helper).  It  is  intriguing  to  speculate  that  these  cells may  be 
multipotential  stem cells, rather  than  committed T  cell progenitors.  Studies in 
progress are  aimed  at  isolating  these  cells to better  characterize  their  surface 
antigens,  arrangement  of  immunoglobulin  and  T  cell  receptor  genes,  their 
production of and response to proliferation- and differentiation-promoting  fac- 
tors, and their potential for multilineage colony formation. 
Finally,  we  have  shown  that  ADA  substrates  in  the  presence  of deoxyco- 
formycin  induced  the  expression  of markers  of myeloid differentiation  by T 
lymphoblastoid  DU.528  cells.  This  finding  supports  our  earlier  proposal  (11)' 
that  in  vivo  deoxycoformycin-induced  lymphoid-to-myeloid  conversion  may 
have resulted  from the effects of ADA substrates on stem cell differentiation, 
rather  than  from  selective cytotoxicity.  An  extension  of this  view is  that  the 
pluripotent stem cell may be a direct target affected by genetic ADA deficiency. 
The  DU.528  cell  line  may  prove  to  be  a  useful  model  for  examining  the 
mechanisms by which purines and other factors influence lymphohematopoietic 
stem cell proliferation and differentiation. 
Summary 
We  have  established  the  DU.528  cell  line  from  the  pretreatment  leukemia 
cells of a patient who underwent a T  lymphoblastic-to-promyelocytic phenotype 
conversion during  treatment  with the adenosine deaminase inhibitor,  deoxyco- 
formycin, The cell line and clones obtained from it by limiting dilution have the 
same karyotype previously found in  the patient's  pretreatment  T  lymphoblasts 
and post-deoxycoformycin treatment promyelocytes. DU.528 cells in continuous 
culture  for  >2  yr  display  a  predominant  undifferentiated  T  lymphoblastoid 
phenotype. These cells spontaneously generate progeny of at least three lineages, 
T  lymphoid,  granulocytic/monocytic, and erythroid.  The surface marker  most 
consistently expressed by DU.528 cells in the undifferentiated  state is the  3A1 1576  A  HUMAN LYMPHOHEMOPOIETIC  STEM CELL  LINE 
antigen,  which  has  been  found  on  prothymocytes in  the  embryonic  thymus. 
Some  undifferentiated  DU.528  cells also  expressed  the  IL-2 receptor,  but  no 
other T  cell differentiation antigens.  Exposure of DU.528  cells to a  variety of 
agents  induced  myeloid  maturation;  adenosine  and  deoxyadenosine,  in  the 
presence  of deoxycoformycin,  induced  expression  of myeloid  differentiation 
antigens.  Our  results suggest  that  DU.528  is a  lymphohematopoietic stem  cell 
line and support the hypothesis that differentiation of pluripotent stem cells may 
be  altered  by  genetic  deficiency of adenosine  deaminase.  DU.528  cells  may 
provide a useful model for examining factors that regulate stem cell proliferation 
and differentiation. 
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